Literature DB >> 29957250

Increased plasma trimethylamine-N-oxide is associated with incident atrial fibrillation.

Gard F T Svingen1, Hui Zuo2, Per M Ueland3, Reinhard Seifert4, Kjetil H Løland4, Eva R Pedersen4, Peter M Schuster4, Therese Karlsson3, Grethe S Tell2, Hall Schartum-Hansen5, Hilde Olset4, Mads Svenningsson4, Elin Strand2, Dennis W Nilsen6, Jan E Nordrehaug3, Indu Dhar7, Ottar Nygård8.   

Abstract

BACKGROUND: Plasma trimethylamine-N-oxide (TMAO) is associated with cardiovascular disease; however specific relationships with cardiac arrhythmias are unknown. We evaluated the association between plasma TMAO and incident atrial fibrillation (AF).
METHODS: Risk associations were explored among 3797 patients with suspected stable angina in the Western Norway Coronary Angiography Cohort (WECAC) and verified in 3143 elderly participants in the community-based Hordaland Health Study (HUSK). Information on endpoints was obtained from nationwide registries.
RESULTS: Median follow-up was 7.3 and 10.8 years in the WECAC and HUSK cohorts, respectively, and 412 (10.9%) and 484 (15.4%) subjects were registered with incident AF. The age and gender adjusted HRs were 1.16, 95% CI 1.05-1.28 and 1.10, 95% CI 1.004-1.19 per 1 SD increase in log-transformed plasma TMAO. Adjusting for hypertension, BMI, smoking, diabetes, or intake of total choline, a TMAO precursor, did not materially influence the risk associations. Among patients in WECAC, further extensive adjustment for other AF risk factors yielded similar results. Adding TMAO to traditional AF risk factors (age, gender, hypertension, BMI, smoking and diabetes) yielded a continuous net reclassification improvement of 0.108, 95% CI 0.015-0.202 and 0.139, 95% CI 0.042-0.235.
CONCLUSIONS: Plasma TMAO was associated with and improved reclassification of incident AF in two independent Norwegian cohorts with long-term follow-up. The relationship was independent of traditional AF risk factors, as well as of dietary choline intake. Our findings motivate further studies to explore endogenous metabolic factors influencing the relationship between TMAO and cardiovascular disease.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Biomarker; Cardiovascular disease risk factors; Choline; Trimethylamine-N-oxide

Mesh:

Substances:

Year:  2018        PMID: 29957250     DOI: 10.1016/j.ijcard.2018.04.128

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  23 in total

Review 1.  Microbiota in cerebrovascular disease: A key player and future therapeutic target.

Authors:  Shuichi Tonomura; Masafumi Ihara; Robert P Friedland
Journal:  J Cereb Blood Flow Metab       Date:  2020-04-20       Impact factor: 6.200

2.  Choline Metabolism and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Study.

Authors:  Christopher Papandreou; Mònica Bulló; Pablo Hernández-Alonso; Miguel Ruiz-Canela; Jun Li; Marta Guasch-Ferré; Estefanía Toledo; Clary Clish; Dolores Corella; Ramon Estruch; Emilio Ros; Montserrat Fitó; Angel Alonso-Gómez; Miquel Fiol; José M Santos-Lozano; Lluís Serra-Majem; Liming Liang; Miguel A Martínez-González; Frank B Hu; Jordi Salas-Salvadó
Journal:  Clin Chem       Date:  2021-01-08       Impact factor: 8.327

Review 3.  Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications.

Authors:  Monika Gawałko; Thomas A Agbaedeng; Arnela Saljic; Dominik N Müller; Nicola Wilck; Renate Schnabel; John Penders; Michiel Rienstra; Isabelle van Gelder; Thomas Jespersen; Ulrich Schotten; Harry J G M Crijns; Jonathan M Kalman; Prashanthan Sanders; Stanley Nattel; Dobromir Dobrev; Dominik Linz
Journal:  Cardiovasc Res       Date:  2022-08-24       Impact factor: 13.081

Review 4.  The role of the gut microbiota in health and cardiovascular diseases.

Authors:  Lu Wang; Shiqi Wang; Qing Zhang; Chengqi He; Chenying Fu; Quan Wei
Journal:  Mol Biomed       Date:  2022-10-11

5.  Gut Microbiota-Derived Trimethylamine N-Oxide and Kidney Function: A Systematic Review and Meta-Analysis.

Authors:  Yan Zeng; Man Guo; Xia Fang; Fangyuan Teng; Xiaozhen Tan; Xinyue Li; Mei Wang; Yang Long; Yong Xu
Journal:  Adv Nutr       Date:  2021-07-30       Impact factor: 8.701

6.  Targeting TMAO and its metabolic pathway for cardiovascular diseases treatment.

Authors:  Zahra Hoseini-Tavassol; Shirin Hasani-Ranjbar
Journal:  J Diabetes Metab Disord       Date:  2021-05-17

Review 7.  Role of the Gut Microbiota in Stroke Pathogenesis and Potential Therapeutic Implications.

Authors:  Kazuo Yamashiro; Naohide Kurita; Takao Urabe; Nobutaka Hattori
Journal:  Ann Nutr Metab       Date:  2021-06-09       Impact factor: 3.374

8.  Gut-microbe derived TMAO and its association with more progressed forms of AF: Results from the AF-RISK study.

Authors:  B O Nguyen; L M G Meems; M van Faassen; H J G M Crijns; I C van Gelder; F Kuipers; M Rienstra
Journal:  Int J Cardiol Heart Vasc       Date:  2021-05-24

Review 9.  Sugar Fructose Triggers Gut Dysbiosis and Metabolic Inflammation with Cardiac Arrhythmogenesis.

Authors:  Wan-Li Cheng; Shao-Jung Li; Ting-I Lee; Ting-Wei Lee; Cheng-Chih Chung; Yu-Hsun Kao; Yi-Jen Chen
Journal:  Biomedicines       Date:  2021-06-25

10.  Gut-microbiota derived TMAO: A risk factor, a mediator or a bystander in the pathogenesis of atrial fibrillation?

Authors:  Monika Gawałko; Dominik Linz; Dobromir Dobrev
Journal:  Int J Cardiol Heart Vasc       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.